Immunocore Holdings PLC ADR IMCR
News
Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma
Immunocore to present at upcoming investor conferences
Immunocore reports second quarter financial results and provides a business update
Immunocore to report second quarter 2026 financial results and host call on August 6, 2026
